Scarica l'app Stockscreener
3.05
0.33%
-0.01
Dopo l'orario di chiusura:
3.12
0.07
+2.30%
Precedente Chiudi:
$3.06
Aprire:
$3.09
Volume 24 ore:
114.76K
Relative Volume:
1.64
Capitalizzazione di mercato:
$28.24M
Reddito:
$4.01M
Utile/perdita netta:
$-26.97M
Rapporto P/E:
-1.0267
EPS:
-2.9707
Flusso di cassa netto:
$-23.45M
1 W Prestazione:
+5.54%
1M Prestazione:
-21.39%
6M Prestazione:
-69.32%
1 anno Prestazione:
-63.99%
Intervallo 1D:
$2.9474
$3.1379
Intervallo di 1 settimana:
$2.8702
$3.27
Portata 52W:
$2.815
$13.13
Cervomed Inc Stock (CRVO) Company Profile
Nome
Cervomed Inc
Settore
Industria
Telefono
(617) 744-4400
Indirizzo
20 PARK PLAZA, BOSTON
Compare CRVO vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
3.05 | 28.33M | 4.01M | -26.97M | -23.45M | -2.9707 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-03-13 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2024-12-17 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-12-11 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2024-12-11 | Downgrade | Morgan Stanley | Overweight → Underweight |
| 2024-12-10 | Downgrade | D. Boral Capital | Buy → Hold |
| 2024-12-06 | Iniziato | ROTH MKM | Buy |
| 2024-12-05 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-18 | Iniziato | Chardan Capital Markets | Buy |
| 2024-07-26 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-15 | Iniziato | Canaccord Genuity | Buy |
| 2020-11-17 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2018-03-21 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Cervomed Inc Borsa (CRVO) Ultime notizie
CRVO Q1 2026 Earnings: EPS Misses EstimatesProfit Margin Analysis - Newser
CRVO Q1 2026 Earnings: EPS Miss Reflects Continued Clinical InvestmentReal Trader Network - Newser
CervoMed Stock Slides Into Long Weekend as CRVO’s Cash Clock Tests Phase 3 Hopes - Bez Kabli
CervoMed Inc. (CRVO) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Modest Stock DeclineNet Profit Margin - Newser
CRVO Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Clinical Stage Company Reports No RevenueEarnings Momentum Score - Newser
What CervoMed (CRVO)'s -2.75% Decline Means for Investors 2026-05-21Put Dominated - Newser
CervoMed (CRVO) Q1 2026 Results Fall Short — EPS $-0.86, Revenue $N/AAnnual Financial Report - Newser
CervoMed Inc. Announces Q1 2026 Financial Results, Corporate Updates, and Phase 3 DLB Trial Plans - Minichart
How to Value CervoMed (CRVO) After Q1 2026? EPS Not Disclosed; R - GuruFocus
CervoMed Expects EXPERTS-ALS to Dose First Patient With ALS With Neflamapimod by End of 2026 >CRVO - Moomoo
CervoMed Highlights Q1 Results and Neflamapimod Progress - TipRanks
CervoMed (NASDAQ: CRVO) posts Q1 2026 loss and cash runway into Q3 2026 - Stock Titan
CervoMed (CRVO) Reports Significant Decline in Grant Revenue and Increased Net Loss - GuruFocus
CervoMed posts smaller-than-expected Q1 net loss - TradingView
Press Release: CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates - Moomoo
CervoMed announced plans to initiate a Phase III clinical trial in the second half of 2026 to evaluate the efficacy and safety of its candidate drug Neflamapimod in patients with dementia with Lewy bodies (DLB). - Bitget
Number of shareholders of CervoMed Inc. – NASDAQ:CRVO - TradingView
CervoMed Inc. Q1 2026 10-Q: Financial Results, Risk Factors, and Forward-Looking Statements Overview - Minichart
CervoMed Inc reports results for the quarter ended March 31Earnings Summary - TradingView
CervoMed Inc. 1Q 2026: Revenue $0 Net income ($7.96M), EPS ($0.86) — 10-Q Summary - TradingView
CRVO: Net loss increased to $8.0 million in Q1 2026, with cash runway concerns due to lack of new funding - TradingView
CervoMed Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
CervoMed (CRVO) widens quarterly loss and warns of going concern risk - Stock Titan
CRVO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
CRVO Stock Price, Quote & Chart | CERVOMED INC (NASDAQ:CRVO) - ChartMill
Morgan Stanley reporting units hold 8.0% of CervoMed (CRVO) in Schedule 13G/A - Stock Titan
CervoMed Inc expected to post a loss of 78 cents a shareEarnings Preview - TradingView
What CervoMed (CRVO) is doing to stay ahead (Breakdown Watch) 2026-05-08Community Momentum Stocks - newser.com
CervoMed (CRVO) outlines 2026 virtual meeting, board slate and pay plan vote - Stock Titan
[ARS] CervoMed Inc. SEC Filing - Stock Titan
CRVO Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
CRVO (CervoMed) posts wider than expected Q4 2025 loss even as shares notch mild daily gains.Crowd Risk Alerts - Newser
H.C. Wainwright Maintains CervoMed(CRVO.US) With Buy Rating, Maintains Target Price $25 - Moomoo
CRVO Maintained by D. Boral Capital -- Price Target Steady at $3 - GuruFocus
CervoMed Highlights Positive Phase 2b Neflamapimod MRI Results - TipRanks
CRVO (CervoMed Inc.) reports wider-than-expected Q4 2025 loss driven by elevated clinical research spending.Decline Phase - Cổng thông tin điện tử Tỉnh Sơn La
Neflamapimod MRI data in dementia with Lewy bodies from CervoMed (NASDAQ: CRVO) - Stock Titan
CervoMed (CRVO) Shows Promise in DLB Treatment with Neflamapimod - GuruFocus
CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies - ChartMill
Drug candidate boosted brain region tied to Lewy body dementia - Stock Titan
What should investors watch for CervoMed (CRVO) stock (Smart Money Exits) 2026-04-20Public Sentiment - Cổng thông tin điện tử tỉnh Lào Cai
Is CervoMed (CRVO) stock a good candidate for diversification (Investor Concern) 2026-04-18Community Pattern Alerts - Xã Châu Thành
Operating cash flow per share of CervoMed Inc. – FWB:DP8 - TradingView — Track All Markets
CRVO Should I Buy - Intellectia AI
CRVO.O PE Ratio & Valuation, Is CRVO.O Overvalued - Intellectia AI
CRVO.O Forecast — Price Prediction for 2026. Should I Buy CRVO.O? - Intellectia AI
Buyout Rumor: Does CervoMed Inc have strong fundamentalsWeekly Stock Analysis & Verified Momentum Watchlists - baoquankhu1.vn
CRVO.O Technical Analysis & Stock Price Forecast - Intellectia AI
CRVO.O Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Lewy Body Dementia Market: Accelerating Growth And Pipeline Impact By 2034 Delveinsight Cognition Therapeutics, Keiferx, Eisai, EIP Pharma, Sun Pharma, Axovant Sciences Ltd., Cognition Therapeutics - Mena FN
Cervomed Inc Azioni (CRVO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cervomed Inc Azioni (CRVO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Winton Matthew | Chief Commercial and Business |
Nov 18 '25 |
Buy |
7.95 |
1,500 |
11,925 |
15,000 |
| Gregoire Sylvie | Director |
Nov 17 '25 |
Buy |
8.46 |
10,807 |
91,427 |
12,500 |
| Gregoire Sylvie | Director |
Nov 17 '25 |
Buy |
8.46 |
10,793 |
91,309 |
1,484,078 |
| ELDER WILLIAM ROBERT | CFO, GC & Secretary |
Nov 18 '25 |
Buy |
8.32 |
2,500 |
20,800 |
12,500 |
| ELDER WILLIAM ROBERT | CFO, GC & Secretary |
Nov 17 '25 |
Buy |
8.45 |
1,000 |
8,450 |
10,000 |
| ALAM JOHN J | CEO & President |
Nov 17 '25 |
Buy |
8.46 |
10,807 |
91,427 |
1,484,078 |
| ALAM JOHN J | CEO & President |
Nov 17 '25 |
Buy |
8.46 |
10,793 |
91,309 |
12,500 |
| Gregoire Sylvie | Director |
Nov 13 '25 |
Buy |
7.51 |
4,447 |
33,397 |
1,471,578 |
| Gregoire Sylvie | Director |
Nov 14 '25 |
Buy |
7.57 |
1,707 |
12,922 |
1,473,285 |
| Gregoire Sylvie | Director |
Nov 14 '25 |
Buy |
7.55 |
1,693 |
12,782 |
1,693 |
0.98%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):